Skip to main content
Pharmena S.A. logo

Pharmena S.A. — Investor Relations & Filings

Ticker · PHR ISIN · PLPHRMN00011 LEI · 259400RHT936BBKW0955 WAR Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2022-02-14 Capital/Financing Update
Country PL Poland
Listing WAR PHR

About Pharmena S.A.

https://www.pharmena.eu/

Pharmena S.A. is a specialty healthcare company focused on the development and commercialization of innovative products based on its patented active ingredient, 1-MNA. This molecule is a naturally occurring metabolite of niacin (vitamin B3) that plays a crucial role in cellular metabolism. The company's technology leverages the ability of 1-MNA to optimize the levels of the coenzyme NAD+, which decline with age and are vital for cellular function and regeneration. The product portfolio includes specialized cosmeceuticals, such as the Dermena line for hair loss, and dietary supplements designed to address the effects of cellular aging.

Recent filings

Filing Released Lang Actions
Podpisanie aneksów do istotnych umów pożyczek - Content (PL)
Capital/Financing Update Classification · 95% confidence The document is a current report (raport bieżący) from a Polish issuer (Pharmena S.A.) detailing the amendment (aneks) of significant loan agreements with related parties (Pelion S.A., CEO, Chairman of the Supervisory Board). The content focuses on changes to repayment terms and interest calculations for these loans. This type of disclosure, concerning material financial arrangements and related party transactions, falls under general corporate financing or material event reporting. Since it is not a full annual report (10-K), an earnings release (ER), or a specific dividend/share change notice, it best fits the category for Capital/Financing Updates (CAP) or, given its nature as a specific material event disclosure, potentially a general Regulatory Filing (RNS). However, because it explicitly details changes to financing agreements (loans), CAP is a strong candidate. Given the context of Polish regulatory filings, these specific material event disclosures often fall under a broader category if a more specific one isn't available. Since the core subject is the modification of financing terms, 'Capital/Financing Update' (CAP) is the most appropriate specific classification over the general 'RNS'. The document length is short, but it is the primary disclosure itself, not an announcement of another document.
2022-02-14 Polish
Terminy publikacji raportów okresowych w roku 2022 - Content (PL)
Report Publication Announcement Classification · 100% confidence The document text, written in Polish, explicitly details the schedule ('harmonogram') for publishing periodic reports (annual, quarterly, semi-annual) for the year 2022. It lists specific dates for the release of the consolidated annual report, Q1 report, H1 report, and Q3 report. The text also cites specific Polish financial regulations (§ 62 ust. 1 Rozporządzenia Ministra Finansów) regarding the content and publication of these reports. Since the document's sole purpose is to announce *when* future reports will be released, it fits the definition of a Report Publication Announcement (RPA). It is not the report itself (like 10-K or IR), nor is it a general regulatory filing (RNS) given the specific nature of announcing a reporting schedule.
2022-01-28 Polish
Pharmena_Raport za III kwartał 2021
Interim / Quarterly Report Classification · 100% confidence The document is a detailed table of contents for a quarterly report (specifically for the period ending September 30, 2021) for Pharmena S.A. It includes sections for consolidated financial statements, notes, and management commentary. Since it contains substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. 9M 2021
2021-11-26 Polish
Wyznaczenie pierwszego dnia notowania akcji serii F (po asymilacji tych akcji) na rynku regulowanym GPW - Content (PL)
Share Issue/Capital Change Classification · 98% confidence The document text is a formal announcement from the Management Board of Pharmena S.A. regarding a decision by the Warsaw Stock Exchange (GPW) Management Board. The core content details the admission and introduction of a new series of shares (Series F) into stock exchange trading on the parallel market, effective October 11, 2021. This action directly relates to the issuance or listing of new shares/capital structure changes. This aligns best with the 'Share Issue/Capital Change' category (SHA). It is not a general regulatory filing (RNS) because it concerns a specific capital event, nor is it a delisting (DLST). Given the content focuses on the admission of new shares to trading, SHA is the most precise fit.
2021-10-04 Polish
210827_PHR_oswiadczenie zarządu_rzetelność_1H2021
Earnings Release Classification · 99% confidence The document title is "OŚWIADCZENIE ZARZĄDU W SPRAWIE RZETELNOŚCI JEDNOSTKOWEGO I SKONSOLIDOWANEGO SPRAWOZDANIA FINANSOWEGO ZA I PÓŁROCZE 2021," which translates to "MANAGEMENT STATEMENT ON THE FAIRNESS OF THE INDIVIDUAL AND CONSOLIDATED FINANCIAL STATEMENTS FOR THE FIRST HALF OF 2021." This document is a formal declaration by the management regarding the accuracy and fairness of the financial statements for the first half of the year (I półrocze 2021). This content strongly aligns with the definition of an Interim / Quarterly Report (IR), as it pertains to the financial results of a period shorter than a year. Although it is a statement *about* the report, in many regulatory contexts, the management assertion accompanying the interim report is filed as part of the comprehensive interim reporting package. Given the specific focus on half-year financial statements and management's assertion of their fairness, the most appropriate classification is Interim / Quarterly Report (IR). It is not a mere announcement of publication (RPA) because it contains substantive management assertions regarding the financial data itself. H1 2021
2021-08-27 Polish
210828_PHR_oswiadczenie zarządu_wybór audytora_1H2021
Audit Report / Information Classification · 95% confidence The document title is "OŚWIADCZENIE ZARZĄDU W SPRAWIE PODMIOTU UPRAWNIONEGO DO BADANIA SPRAWOZDAŃ FINANSOWYCH" which translates to "MANAGEMENT STATEMENT REGARDING THE ENTITY AUTHORIZED TO AUDIT FINANCIAL STATEMENTS". The text explicitly states that the Management Board has selected an auditing firm to review the semi-annual condensed individual and consolidated financial statements for the first half of 2021, confirming the auditor meets independence and professional standards. This content directly relates to the audit process and the selection/confirmation of the auditor, which aligns best with the Audit Report / Information category (AR), as it is a formal statement concerning the audit function, even though it is not the audit report itself. It is a specific declaration related to the audit process. H1 2021
2021-08-27 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.